MiMedx Group's EPIEFFECT Outperforms Standard Care in Diabetic Foot Ulcer Treatment

MiMedx Group's EPIEFFECT product has interim trial data showing it significantly outperforms standard care in treating nonhealing diabetic foot ulcers, with a 98.5% statistical probability of being more effective. This may draw new clinical and market attention, influencing MiMedx Group's investment narrative and growth outlook. However, the company still faces key risks, including upcoming Medicare reimbursement changes that could pressure future margins and growth.